What happened: TDB-DST support for GrivaVision commercialization

The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, entered into an agreement with M/s Griva Healthcare Pvt. Ltd., Visakhapatnam, to support the manufacturing and commercialization of “GrivaVision”. The support targets scaling an indigenous portable digital colposcope with AI-assisted capabilities for early detection of cervical pre-cancerous lesions. The agreement’s stated outcome is commercial-scale production and wider deployment of GrivaVision for cervical cancer screening beyond specialised settings.

What GrivaVision is (device features and standards claimed)

GrivaVision is described as a portable diagnostic platform intended for visualization of the vaginal canal and examination of cervical lesions during routine clinical examinations. The device is reported to integrate a high-definition camera, a built-in display, a user-friendly interface, advanced optics, and indigenous AI-enabled software. The software is reported as Automated Visual Evaluation (AVE) standards compatible with WHO-approved AVE standards and also reported as compliant with ABDM (Ayushman Bharat Digital Mission), enabling integration with India’s digital health ecosystem.

Regulatory and quality claims in the agreement include the following: GrivaVision is classified as a Class B non-invasive medical device, it carries a CDSCO Class B manufacturing licence, and development is stated to follow ISO 13485 quality standards (a standard for medical device quality management systems).

Background and earlier position: indigenous R&D and localization approach

Related current affairs